Novartis is set to invest $23 billion in US-based manufacturing and research and development (R&D) over the next five years, ...

Platinum Asset Management’s flagship international fund initiated positions in several pharmaceutical companies in the ...

Hikma buys rights to FDA-approved cancer treatment trametinib, a generic version of Novartis' (NVS) Mekinist, with 180 days ...

A three-judge panel wrestled Thursday with Novartis AG’s challenge against the FDA over its approval of a generic version of ...

Shares MSCI Switzerland ETF's high allocation to Nestle, Roche, and Novartis poses diversification risks. Read why EWL is a ...

Real Chemistry, a 2024 MM+M Agency 100 honoree, appointed Cali Howitt, PhD, as president of U.S. medical and executive leader for its promotional and medical affairs business in the U.S. General ...

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, ...

Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

Swiss pharmaceutical giant Novartis announced it will spend $23 billion to build and expand 10 facilities in the United ...

Swiss pharmaceutical giant Novartis announced Thursday that it plans to build a $1.1 billion research hub in San Diego as ...

Two days after pharma companies sounded an alarm that their investments were headed out of Europe, Novartis AG has announced ...